<DOC>
	<DOC>NCT00358488</DOC>
	<brief_summary>This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.</brief_summary>
	<brief_title>Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Subjects with documented history of persistent asthma using corticosteroids at a total daily dose of 200 to 200mcg of FP or equivalent corticosteroid Female subjects only using acceptable birth control method Nonsmokers FEV1 between 60 and 90% predicted Increase in FEV1 12% or greater and 300mL and greater after salbutamol use Exclusion criteria: Past or present disease conditions Normal screening Holter ECG Respiratory tract infection within 4 weeks of screening History of life threatening asthma Previous use of COA</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Asthmatic patients</keyword>
	<keyword>GSK159797</keyword>
	<keyword>Efficacy</keyword>
</DOC>